Study summary
Half of the patients in the study will be given bempedoic acid, the other half will be given a placebo. They will not know which they are taking.
As you will be taking part in the study from your site, you will need to monitor cholesterol levels in your trial patients and document any CVD-related changes (e.g. heart attack, stroke, hospital admission).